Concordant message of different inflammatory markers in patients with rheumatoid arthritis

被引:17
作者
Arvidsson, NG
Gudbjörnssor, B
Hällgren, R
Larsson, A [1 ]
机构
[1] Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden
[2] Univ Uppsala Hosp, Dept Rheumatol, S-75185 Uppsala, Sweden
关键词
D O I
10.3109/03009739809178943
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The acute phase reaction is an unspecific response to inflammatory stimuli characterized by alterations in the concentration of several plasma proteins. It is of great clinical value to monitor the inflammatory state in patients with rheumatoid arthritis. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are the assays most widely used to measure the acute phase response, but there are also several other inflammatory markers (e.g. fibrinogen, haptoglobin, alpha(1)-acid glycoprotein, alpha(1)-antitrypsin, interleukins (IL), serum amyloid component A (SAA)). We have studied the interrelationships between several of these markers (ESR, Haptoglobin, Fibrinogen, CRP, SAA and IL-6) in rheumatoid arthritis patients. There was a good correlation between all acute phase markers in serum (p<.01). We found especially strong correlations between S-CRP and SAA (p<.000001) and between ESR and P-fibrinogen (p=.000004). The strong correlation indicates that P-fibrinogen could be used instead of ESR in monitoring rheumatoid arthritis patients. This would increase the specificity of the examination as ESR may be influenced by several factors other than the inflammatory response. There were no significant correlations between acute phase markers in serum or plasma and clinical index.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 22 条
[1]  
AMETT FC, 1988, ARTHRITIS RHEUM, V31, P315
[2]  
[Anonymous], 1921, Acta Med Scand
[3]   The timing of glucocorticoid administration in rheumatoid arthritis [J].
Arvidson, NG ;
Gudbjornsson, B ;
Larsson, A ;
Hallgren, R .
ANNALS OF THE RHEUMATIC DISEASES, 1997, 56 (01) :27-31
[4]   Selection and use of laboratory tests in the rheumatic diseases [J].
Barland, P ;
Lipstein, E .
AMERICAN JOURNAL OF MEDICINE, 1996, 100 :S16-S23
[5]   Fibrinogen is a predictor of mortality in coronary heart disease patients [J].
Benderly, M ;
Graff, E ;
ReicherReiss, H ;
Behar, S ;
Brunner, D ;
Goldbourt, U .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (03) :351-356
[6]   RELATION OF FIBRINOGEN TO PRESENCE AND SEVERITY OF CORONARY-ARTERY DISEASE IS INDEPENDENT OF OTHER COEXISTING HEART-DISEASE [J].
BOLIBAR, I ;
KIENAST, J ;
THOMPSON, SG ;
MATTHIAS, R ;
NIESSNER, H ;
FECHTRUP, C .
AMERICAN HEART JOURNAL, 1993, 125 (06) :1601-1605
[7]  
BULL BS, 1993, J CLIN PATHOL, V46, P198
[8]  
DAVIS MJ, 1990, BRIT J RHEUMATOL, V29, P111
[9]   MEASURING PLASMA-FIBRINOGEN TO PREDICT STROKE AND MYOCARDIAL-INFARCTION [J].
DIMINNO, G ;
MANCINI, M .
ARTERIOSCLEROSIS, 1990, 10 (01) :1-7
[10]   DIAGNOSTIC-VALUE OF C-REACTIVE PROTEIN MEASUREMENT DOES NOT JUSTIFY REPLACEMENT OF THE ERYTHROCYTE SEDIMENTATION-RATE IN DAILY GENERAL-PRACTICE [J].
DINANT, GJ ;
DEKOCK, CA ;
VANWERSCH, JWJ .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1995, 25 (05) :353-359